Flourtown, PA, United States of America

Franck Skobieranda

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 19(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Franck Skobieranda: Innovator in Asthma Treatment

Introduction

Franck Skobieranda is a notable inventor based in Flourtown, PA (US). He has made significant contributions to the field of medicine, particularly in the treatment of asthma. His innovative approach focuses on utilizing interleukin-4 receptor antagonists to provide therapeutic solutions for patients suffering from asthma and related conditions.

Latest Patents

Franck Skobieranda holds a patent for "Methods for treating or preventing asthma by administering an IL-4R antagonist." This invention outlines methods for treating or preventing asthma by administering a therapeutic composition that includes an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody. This patent represents a significant advancement in asthma treatment, offering new hope for patients.

Career Highlights

Throughout his career, Franck has worked with prominent companies in the biotechnology and pharmaceutical sectors. He has been associated with Sanofi Biotechnology and Regeneron Pharmaceuticals, Inc., where he has contributed to various research and development projects aimed at improving patient outcomes.

Collaborations

Franck has collaborated with esteemed colleagues in his field, including Gianluca Pirozzi and Yongtao Li. These collaborations have further enhanced his research and development efforts, leading to innovative solutions in asthma treatment.

Conclusion

Franck Skobieranda's work in developing methods for treating asthma showcases his dedication to improving healthcare through innovation. His contributions to the field are invaluable, and his patent reflects a promising advancement in asthma therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…